Colon Cancer: CTSU 80702 (Iowa Cancer Specialists)

CTSU CALGB/SWOG 80702: A Phase III Trial of 6 versus 12 Treatments of Adjuvant Folfox Plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer

Objective

This randomized phase III trial is studying giving patients FOLFOX which includes oxaliplatin, leucovorin, and 5-fluorouracil (5-FU) to compare how well they work when given together with or without celecoxib in treating patients with stage III colon cancer previously treated with surgery.

For more information on this trial, visit the National Cancer Institute.

Principal Investigator(s)
George Kovach

Clinical Trial Categories

  • Colon
  • Cancer
Sponsor(s)
Cancer and Leukemia Group B
Cancer Trials Support Unit
SWOG
Contact
Kim Turner, R.N. at 563-421-1908
or turnerk@genesishealth.com

Location

  • Cancer Care Institute
    1351 West Central Park
    Pavilion 1, 1st Floor
    Davenport, IA 52804
    Main: 563-421-1900
    Alternate: 800-446-6088
    Fax: 563-421-1938

Contact Us

For more information about our research program and IRB, please contact:

Research Support Office
563-421-7955

Email